LENSAR (NASDAQ:LNSR) and UFP Technologies (NASDAQ:UFPT) Head to Head Analysis

LENSAR (NASDAQ:LNSR) and UFP Technologies (NASDAQ:UFPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for LENSAR and UFP Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENSAR 0 0 1 0 3.00
UFP Technologies 0 0 2 0 3.00

LENSAR currently has a consensus price target of $20.00, suggesting a potential upside of 128.31%. Given LENSAR’s higher probable upside, equities research analysts clearly believe LENSAR is more favorable than UFP Technologies.

Insider and Institutional Ownership

58.8% of LENSAR shares are owned by institutional investors. Comparatively, 78.2% of UFP Technologies shares are owned by institutional investors. 17.3% of LENSAR shares are owned by insiders. Comparatively, 10.0% of UFP Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares LENSAR and UFP Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
UFP Technologies 7.59% 7.80% 6.73%

Earnings and Valuation

This table compares LENSAR and UFP Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LENSAR $26.38 million 3.63 -$19.77 million ($4.28) -2.05
UFP Technologies $179.37 million 2.41 $13.37 million $1.77 32.45

UFP Technologies has higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than UFP Technologies, indicating that it is currently the more affordable of the two stocks.


UFP Technologies beats LENSAR on 9 of the 12 factors compared between the two stocks.


LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

About UFP Technologies

UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.

Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.